These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22622126)

  • 1. [Cardioprotection in women with neoplastic disease].
    Cardinale D; Colombo A; Bacchiani G
    G Ital Cardiol (Rome); 2012 Jun; 13(6):461-8. PubMed ID: 22622126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury.
    Jones M; O'Gorman P; Kelly C; Mahon N; Fitzgibbon MC
    Ann Clin Biochem; 2017 Jan; 54(1):149-157. PubMed ID: 27170025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
    Cardinale D; Colombo A; Sandri MT; Lamantia G; Colombo N; Civelli M; Martinelli G; Veglia F; Fiorentini C; Cipolla CM
    Circulation; 2006 Dec; 114(23):2474-81. PubMed ID: 17101852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of afterload reduction in the prevention of late anthracycline cardiomyopathy.
    Silber JH
    Pediatr Blood Cancer; 2005 Jun; 44(7):607-13. PubMed ID: 15795884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiotoxicity of anthracyclines].
    Costache II; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic prevention of anthracycline-induced cardiomyopathy.
    Maradia K; Guglin M
    Cardiol Rev; 2009; 17(5):243-52. PubMed ID: 19690476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy.
    Janbabai G; Nabati M; Faghihinia M; Azizi S; Borhani S; Yazdani J
    Cardiovasc Toxicol; 2017 Apr; 17(2):130-139. PubMed ID: 27003392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature.
    Wojtacki J; Lewicka-Nowak E; Leśniewski-Kmak K
    Med Sci Monit; 2000; 6(2):411-20. PubMed ID: 11208348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
    Pouillart P
    Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anthracycline-induced cardiomyopathy].
    Roul G; Cohen C; Lieber A
    Presse Med; 2009 Jun; 38(6):987-94. PubMed ID: 19423276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac Toxicity: Using Angiotensin-Converting Enzyme Inhibitors to Prevent Anthracycline-Induced Left Ventricular Dysfunction and Cardiomyopathy.
    Kobza C
    Clin J Oncol Nurs; 2021 Jun; 25(3):259-266. PubMed ID: 34019025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
    Conklin KA
    Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy.
    Pinarli FG; Oğuz A; Tunaoğlu FS; Karadeniz C; Gökçora N; Elbeg S
    Pediatr Blood Cancer; 2005 Apr; 44(4):370-7. PubMed ID: 15602715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of biomarkers in chemotherapy-induced cardiotoxicity.
    Cardinale D; Sandri MT
    Prog Cardiovasc Dis; 2010; 53(2):121-9. PubMed ID: 20728699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies.
    Cadeddu C; Mercurio V; Spallarossa P; Nodari S; Triggiani M; Monte I; Piras R; Madonna R; Pagliaro P; Tocchetti CG; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e64-e75. PubMed ID: 27755244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
    Spallarossa P; Maurea N; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e84-e92. PubMed ID: 27755246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevention of anthracycline cardiotoxicity].
    Rossetti R
    Suppl Tumori; 2004; 3(4):S117-9. PubMed ID: 15206234
    [No Abstract]   [Full Text] [Related]  

  • 19. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
    Scully RE; Lipshultz SE
    Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.